Logo

UTMD

Utah Medical Products, Inc.

UTMD

Utah Medical Products, Inc. • NASDAQ
$56.35 ▲ 1.22% (+0.68)
Market Cap $180.53 M
52w High $65.56
52w Low $51.26
Dividend Yield 1.22%
P/E 15.92
Volume 9.46K
Outstanding Shares 3.20M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $9.812M ▼ $2.449M ▲ $2.631M ▼ 26.814% ▼ $0.79 ▼ $4.062M ▼
Q2-2025 $9.953M ▲ $1.86M ▼ $3.048M ▲ 30.624% ▼ $0.92 $4.581M ▲
Q1-2025 $9.71M ▲ $2.385M ▼ $3.041M ▲ 31.318% ▼ $0.92 ▲ $4.188M ▲
Q4-2024 $9.158M ▼ $2.393M ▲ $2.902M ▼ 31.688% ▼ $0.86 ▼ $3.984M ▼
Q3-2024 $10.005M $1.934M $3.563M 35.612% $1.02 $4.919M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $84.267M ▲ $121.975M ▲ $3.723M ▲ $118.252M ▲
Q2-2025 $82.179M ▼ $120.802M ▼ $3.269M ▼ $117.533M ▲
Q1-2025 $83.325M ▲ $122.519M ▼ $5.472M ▲ $117.047M ▼
Q4-2024 $82.976M ▼ $122.538M ▼ $5.111M ▼ $117.427M ▼
Q3-2024 $88.452M $129.694M $5.497M $124.197M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $3.048M ▲ $2.873M ▼ $-51K ▲ $-4.488M ▼ $-1.146M ▼ $2.822M ▼
Q1-2025 $3.041M ▲ $4.464M ▲ $-184K ▼ $-4.238M ▲ $349K ▲ $4.28M ▲
Q4-2024 $2.902M ▼ $2.937M ▼ $-9K ▲ $-7.747M ▼ $-5.476M ▼ $2.928M ▼
Q3-2024 $3.563M ▲ $3.856M ▲ $-89K ▲ $-4.918M ▲ $-767K ▲ $3.993M ▲
Q2-2024 $3.453M $2.762M $-115K $-7.19M $-4.589M $2.647M

Five-Year Company Overview

Income Statement

Income Statement Revenue over the past five years has been steady rather than fast‑growing, with a small pullback in the most recent year. Despite that slowdown, profitability remains strong: the company keeps a large share of each sales dollar as gross profit and still posts healthy operating and net income. Earnings per share have climbed meaningfully compared with 2020, even though they slipped from their recent peak, reflecting some current business headwinds but not a breakdown in the underlying economics. Overall, the income statement suggests a mature, profitable niche business experiencing a softer patch rather than a structural decline.

Balance Sheet

Balance Sheet The balance sheet is very conservative and cash‑rich. The company carries no debt, relies entirely on shareholder equity, and holds a large cash position relative to its total assets. Equity has trended upward over time, showing that profits have been retained and added to the firm’s net worth. This combination of strong liquidity, no leverage, and consistent book value growth points to a financially resilient company that has room to absorb shocks and optionality for future investments or strategic moves.

Cash Flow

Cash Flow Cash generation is a clear strength. Operating cash flow has consistently been positive and closely tracks reported earnings, which indicates that profits are backed by real cash, not just accounting. Free cash flow is almost the same as operating cash flow because capital spending has been very light, so most cash generated is available for dividends, buybacks, or reserves. The flip side is that low capital investment may also signal limited expansion or relatively modest physical growth needs, so future growth will likely hinge more on product innovation and market reach than on heavy new facilities.

Competitive Edge

Competitive Edge Utah Medical Products competes by going deep, not broad. It focuses on narrow but important niches such as women’s health, obstetrics, gynecology, and neonatal intensive care, where specialized know‑how and clinician trust matter more than sheer size. Its advantages include proprietary product designs, strong quality and regulatory records, and in‑house manufacturing that supports high margins and tight quality control. This creates a defensible position in its chosen segments. However, as a smaller player, it remains exposed to risks like dependence on a limited number of OEM customers and international distributors, potential pricing pressure from larger device companies, and the need to continually educate and retain a specialized customer base.

Innovation and R&D

Innovation and R&D Innovation is focused and practical rather than splashy. The company has built a portfolio of specialized devices—such as advanced electrosurgical systems, accurate intrauterine pressure catheters, and neonatal products designed for extremely fragile patients—that aim to solve very specific clinical problems with safety and ease of use in mind. Research and development spending appears disciplined and targeted at extending existing strengths, including work on biopharmaceutical pressure sensors that could open an adjacent market. Because the product pipeline is not heavily publicized, there is some uncertainty about the depth and timing of future launches, so longer‑term growth will depend on the company’s ability to keep refreshing and broadening its niche offerings while navigating regulatory pathways.

Summary

Utah Medical Products combines strong profitability, conservative finances, and a focused competitive strategy. The business generates solid margins and reliable cash flow, holds substantial cash with no debt, and has grown its equity base over time. Its strategy of specializing in women’s health and neonatal care, supported by proprietary designs and in‑house manufacturing, has created a durable position in targeted markets rather than broad market dominance. Current challenges—such as softer revenue, issues with a major OEM customer, and disruptions in some international channels—are pressuring growth in the near term but have not undermined the basic financial strength of the company. Looking ahead, the key watchpoints are whether UTMD can re‑accelerate revenue by expanding its product set and customer base, successfully develop newer areas like biopharma sensors, and manage its dependence on a relatively concentrated set of markets and partners.

NEWS

November 4, 2025 · 10:00 AM UTC

Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend

Read more

October 23, 2025 · 9:00 AM UTC

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2025

Read more